Search

everythinglearnresearchcommunity

for

Search:↓

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

The EG7 foam dressing improved wound healing and reduced inflammation better than other treatments.

IL-2 treatment causes skin eruptions and other reversible side effects, and may play a role in psoriasis.

Microneedle arrays deliver botulinum toxin effectively for sweat suppression, similar to injections.

Etretinate was effective for certain skin conditions, but caused side effects like chapped lips, dry mucous membranes, and hair loss.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Hyperbaric oxygen therapy shows promise for multiple sclerosis, but skepticism and funding issues limit tech use in clinics, and outdated single-drug cancer treatments may cause unnecessary side effects.

Microneedles with extracellular vesicles show promise for treating various conditions with targeted delivery.

New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

A new test helps find drugs to treat head and neck cancer by targeting c-Rel.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

A new 3-D bioreactor system improves drug screening and reduces animal testing.

Extracellular vesicles show promise as treatments but need more research for safety and effectiveness.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Manipulating EGFR signaling may help treat hair loss and promote hair growth.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Estradiol stops hair growth in mice, but an antagonist can reverse this effect.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Platelet-derived exosomes offer better regenerative therapy but face challenges in isolation and regulation.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.

Extracellular vesicles show promise for medical use but face challenges in standardization and safety.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.